Cascadian Therapeutics, Inc.
CASC
CASC was delisted on the 8th of March, 2018.
93 hedge funds and large institutions have $132M invested in Cascadian Therapeutics, Inc. in 2015 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 28 increasing their positions, 22 reducing their positions, and 17 closing their positions.
205% more call options, than puts
Call options by funds: $513K | Put options by funds: $168K
27% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 22
0% more funds holding
Funds holding: 93 → 93 (0)
0% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 17
15% less capital invested
Capital invested by funds: $155M → $132M (-$23.5M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$7M |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$3.48M |
| 3 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$2.37M |
| 4 |
DS
DRW Securities
Chicago,
Illinois
|
+$1.47M |
| 5 |
ARTA
A.R.T. Advisors
New York
|
+$1.12M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
-$3.98M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
-$3.68M |
| 3 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$2.87M |
| 4 |
EC
EcoR1 Capital
San Francisco,
California
|
-$2.58M |
| 5 |
QF
QVT Financial
New York
|
-$1.68M |
CASC Hedge Fund Activity: Q4 2015 in Review
93 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Cascadian Therapeutics, Inc. (CASC) for Q4 2015, worth a combined $132M — down 15% from $155M a quarter earlier.
Fund positioning in CASC was balanced in Q4 2015: 17 funds opened new positions, 17 closed out, 28 added to existing stakes and 22 trimmed.
The largest buyer was BVF Inc, adding an estimated $7M. The largest seller was Avoro Capital Advisors, cutting an estimated $3.98M.
- 93 institutional investors held Cascadian Therapeutics, Inc. (CASC) as of Q4 2015, unchanged from Q3 2015.
- Funds reported $132M of Cascadian Therapeutics, Inc. stock for Q4 2015, down 15% quarter-over-quarter.
- 17 funds opened new Cascadian Therapeutics, Inc. positions in Q4 2015 and 17 closed out, a net change of 0 holders.
- The largest Cascadian Therapeutics, Inc. buyer in Q4 2015 was BVF Inc, an estimated $7M added.
- The largest Cascadian Therapeutics, Inc. seller in Q4 2015 was Avoro Capital Advisors, an estimated $3.98M sold.
Based on aggregated 13F filings for Q4 2015.